The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This editorial has been adapted from “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust.”

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

YOU MAY BE INTERESTED IN

Cancer Policy

Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”

Vinay Prasad, FDA’s chief medical and scientific officer and director of the agency’s Center for Biologics Evaluation and Research, has instructed his staff to check with him before continuing to work on ongoing submissions to journals or beginning new contract-funded projects to “ensure that we are not engaging in sunk cost fallacy, not publishing obviously erroneous work, and not being distracted from our core mission.”
By Jacquelyn Cobb
Drugs & Targets

FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer

FDA approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. These approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population.
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account